SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-05-1620. This Article Full Text (PDF) All Versions of this Article: 2003-05-1620v1 102/13/4277    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kell, W. J Articles by Milligan, D. W Search for Related Content PubMed PubMed Citation Articles by Kell, W. J Articles by Milligan, D. W Social Bookmarking                   What's this? Submitted May 29, 2003 Accepted July 26, 2003 Simultaneous administration of Mylotarg (Gemtuzumab Ozogamicin) with intensive chemotherapy in induction, and consolidation in younger patients with acute myeloid leukaemia: a feasibility study William J Kell, Alan K Burnett*, Raj Chopra, John A L Yin, Richard E Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G Prentice, and Donald W Milligan Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom Department of Haematology, Royal Liverpool Hospital, Liverpool, United Kingdom Department of Haematology, St. Bartholomew's Hospital, London, United Kingdom Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom Department of Haematology, Derriford Hospital, Plymouth, United Kingdom Department of Haematology, Heartlands Hospital, Birmingham, United Kingdom * Corresponding author; email: BurnettAK{at}Cardiff.ac.uk. The feasibility of combining Gemtuzumab Ozogamicin (GO, MylotargTM) with intensive chemotherapy as first line treatment of Acute Myeloid Leukaemia was assessed in 72 patients aged 17-59 years, as a prelude to the MRC AML15 Trial. Sixty-four patients received induction chemotherapy [DAT, DA or FLAG-Ida] with GO on day 1. It was possible to give GO 3mg/m2 with course 1, but 6mg/m2 with course 1 or GO in a dose of 3mg/m2, with consecutive courses was not feasible due to hepatotoxicity and delayed haemopoietic recovery. Thirty-one patients were treated in consolidation with MACE or MidAC and GO(3mg/m2), and 23 in induction and consolidation, tolerated GO (3mg/m2) well. Grade 4 liver toxicity and Sinusoidal Obstructive Syndrome was more common in thioguanine containing schedules (p=0.007). Remission with course 1 was seen in 86% of patients. DA and FLAG-Ida with GO in induction achieved CR in 91% of patients and 78% of these patients are in CCR at 8 months. GO given with induction [DA or FLAG-Ida] and consolidation [MACE or MidAC] was well tolerated. These schedules are now being compared in the MRC AML15 Trial in patients under 60 years. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Bornhauser, T. Illmer, U. Oelschlaegel, J. Schetelig, R. Ordemann, M. Schaich, M. Hanel, U. Schuler, C. Thiede, A. Kiani, et al. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2008; 14(17): 5585 - 5593. [Abstract] [Full Text] [PDF] R. Aplenc, T. A. Alonzo, R. B. Gerbing, B. J. Lange, C. A. Hurwitz, R. J. Wells, I. Bernstein, P. Buckley, K. Krimmel, F. O. Smith, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group J. Clin. Oncol., May 10, 2008; 26(14): 2390 - 2395. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] A. K. Burnett and S. Knapper Targeting Treatment in AML Hematology, January 1, 2007; 2007(1): 429 - 434. [Abstract] [Full Text] [PDF] W. Stock Controversies in Treatment of AML: Case-based Discussion Hematology, January 1, 2006; 2006(1): 185 - 191. [Abstract] [Full Text] [PDF] D. C. Taussig, D. J. Pearce, C. Simpson, A. Z. Rohatiner, T. A. Lister, G. Kelly, J. L. Luongo, G.-a. H. Danet-Desnoyers, and D. Bonnet Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia Blood, December 15, 2005; 106(13): 4086 - 4092. [Abstract] [Full Text] [PDF] M. S. Tallman, D. G. Gilliland, and J. M. Rowe Drug therapy for acute myeloid leukemia Blood, August 15, 2005; 106(4): 1154 - 1163. [Abstract] [Full Text] [PDF] E. J. Feldman, J. Brandwein, R. Stone, M. Kalaycio, J. Moore, J. O'Connor, N. Wedel, G. J. Roboz, C. Miller, R. Chopra, et al. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4110 - 4116. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF] R. L. Ilaria Jr. Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues Hematology, January 1, 2005; 2005(1): 188 - 194. [Abstract] [Full Text] [PDF] D. Rosenblum and S. Hirschfeld Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 3128 - 3128. [Abstract] F. Lo-Coco, G. Cimino, M. Breccia, N. I. Noguera, D. Diverio, E. Finolezzi, E. M. Pogliani, E. Di Bona, C. Micalizzi, M. Kropp, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood, October 1, 2004; 104(7): 1995 - 1999. [Abstract] [Full Text] [PDF] M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020